Megan joined Janssen as an Executive Oncology Specialist in 2017. Though she spends her working days seeking a cure for cancer, her connection is personal too: Three of her eight siblings have received cancer diagnoses. In addition, her colleague at Janssen, Steve Roebuck was diagnosed with Stage 3MM in February 2017. She dedicates her R2V ride to Steve.
At Janssen Oncology, we’re shaping the future of cancer treatment. In the process, we’re striving to change expectations of what a cancer diagnosis means. Our purpose is driven by an urgency and commitment to bringing transformational cancer solutions to the people who need them. Passionate about our work, we are driven by the personal connection many of us share with the disease. With our partners, we focus on delivering solutions that make a positive impact on human health. We are part of Janssen Biotech, Inc., and the Janssen Pharmaceutical Companies of Johnson & Johnson.About Janssen Oncology
Click below to learn more about a treatment option for multiple myeloma. If you’re also interested in getting more information from Janssen, sign up for ongoing communications.Learn More